232
Participants
Start Date
December 12, 2018
Primary Completion Date
January 1, 2027
Study Completion Date
July 1, 2028
bendamustine
Given intravenously (IV)
Etoposide
Given intravenously (IV)
Doxorubicin
Given intravenously (IV)
Bleomycin
Given intravenously (IV)
Vincristine
Given intravenously (IV)
Vinblastine
Given intravenously (IV)
Prednisone
Given orally (PO)
Filgrastim
Given subcutaneously (SQ) or IV
Brentuximab Vedotin
Given intravenously (IV)
Cyclophosphamide
Given intravenously (IV)
DTIC
Given intravenously (IV)
Quality of Life Measurements
Quality of Life measurements may be done in low-risk cycles 1 and 2 BEABOVP, intermediate-risk cycles 1, 2 and 3 BEABOVP and high-risk cycles 1 and 2 AEPA and cycles 1, 2, 3, and 4 CAPDac. QOL may be done at year 1, 2 and 5 for all risk groups.
Radiotherapy
Residual node radiotherapy will be given at the end of all chemotherapy only to involved nodes that do not have an AR after 2 cycles of therapy for all risk groups. Radiotherapy will be administered after completion of all chemotherapy upon hematologic count recovery.
St. Jude Affiliate Clinic at Novant Health Hemby Children's Hospital, Charlotte
St. Jude Children's Research Hospital, Memphis
St. Jude Midwest Affiliate - Peoria, Peoria
St. Jude Affiliate Baton Rouge Clinic (Our Lady of the Lakes Regional Medical Center), Baton Rouge
Lucile Packard Children's Hospital Stanford University, Palo Alto
Maine Children's Cancer Program, Scarborough
Massachusetts General Hospital, Boston
Dana Farber Cancer Institute, Boston
Teva Pharmaceuticals USA
INDUSTRY
Seagen Inc.
INDUSTRY
St. Jude Children's Research Hospital
OTHER